BSN

Across TCGA pan-cancer cohorts, BSN Mutation is linked to patient survival in 16 of 34 cancer types, making it a survival-associated BSN data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher BSN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BSN expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

MESO, ACC, and THCA are the cancer types where BSN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
ACC	OS	Median	All	0.124	0.706	<.001	24	view →
THCA	DFS	Median	All	0.063	0.811	<.001	21	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	21	view →
BLCA	OS	Median	II,III,IV	0.895	0.414	.005	19	view →
UCEC	DFS	Median	All	0.915	0.593	.004	16	view →
SARC	OS	Median	All	0.205	0.826	<.001	9	view →
UCS	OS	Median	All	0.190	0.583	.026	6	view →
CESC	DFS	Median	IV	0.053	0.529	<.001	6	view →
READ	DFS	Median	All	0.111	0.799	.001	6	view →
PRAD	DFS	Median	All	0.725	0.935	.019	6	view →
LUSC	DFS	Median	All	0.702	0.361	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

BSN–MESO (OS)

Open the MESO breakdown →